Log in to save to my catalogue

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel...

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1906146063

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial

About this item

Full title

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial

Publisher

United States: Elsevier Inc

Journal title

The American heart journal, 2017-06, Vol.188, p.147-155

Language

English

Formats

Publication information

Publisher

United States: Elsevier Inc

More information

Scope and Contents

Contents

Objective To examine the safety and efficacy of cangrelor in patients with single-vessel disease (SVD) and multi-vessel disease (MVD). Background Cangrelor, an intravenous, rapidly acting P2Y12 inhibitor, is superior to clopidogrel in reducing ischemic events among patients receiving percutaneous coronary intervention (PCI). Methods We studied a mo...

Alternative Titles

Full title

Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1906146063

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1906146063

Other Identifiers

ISSN

0002-8703

E-ISSN

1097-6744

DOI

10.1016/j.ahj.2017.02.031

How to access this item